Plaque Psoriasis

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’

Drs Desai, Shahriari, and Stein Gold examine use and place of traditional systemic treatments in psoriasis.

Dr Stein Gold and Dr Shahriari review steroidal and non-steroidal topical treatments that are available for use in psoriasis.

Approvals by both the FDA and the Chinese NMPA have followed recent clinical trial data on spesolimab injection in GPP patients.

In this post-AAD 2024 interview, Stein Gold commented on her team’s two recent sub-analyses of the phase 4 IMMpulse studies on risankizumab for psoriasis.

Dr Linda Stein Gold and Dr Mona Shahriari discuss post-inflammatory dyspigmentation in patients with skin of color and its impact on patient’s quality of life.

2 expert dermatologists provide tips for communicating, in a culturally sensitive manner, with patients with skin of color.

Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.

April W. Armstrong, MD, MPH, discusses emerging therapies in oral systemics for the treatment of plaque psoriasis and shares developments in TYK2 inhibition.

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

These study findings, presented at AAD 2024, were the results of a recent analysis conducted to assess long-term outcomes among patients with psoriasis.

In this interview segment, Lebwohl discusses the implications of his team’s late-breaking data on bimekizumab for clinical practice.

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

Drs Stein Gold, Shahriari and Desai highlight social and cultural stigma of psoriasis in patients with skin of color and its impact on patient’s quality of life.

Expert dermatologists review the presentation of psoriasis in patients with skin of color and the challenges physicians face in diagnosing psoriasis in this patient population.

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.